Mucosal Vaccines, Adjuvants & Delivery

25-27 September 2013, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 27th September

SESSION 9:
INFLUENZA II

Moderator: Ted Ross (Vaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA)

09.00-09.30
‘Intranasal administration of TLR agonists for influenza VLP vaccines’
Ted Ross (Vaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA)

09.30-10.00
‘Manufacture of an intranasal viral flu vaccine’
Matthew Downham (Medimmune, Liverpool, UK)

10.00-10.20
‘Elaboration of influenza vaccine for mucosal route of immunization’
V.E. Berezin, A.P. Bogoyavlenskyi, A.S.Turmagabetova, P.G. Alexyuk, I.A. Zaitceva, N.S. Sokolova and M.S. Abitaeva (Institute of Microbiology & Virology, Almaty, Kazakhstan)

10.20-10.40
‘Chitosan as an adjuvant for preparation of influenza vaccine’
I. Khalili, M. Fathi Najafi and S. Avagyan (Razi Vaccine & Serum Research Institute, Iran)

10.40-11.10
Coffee Break & Posters

SESSION 10:
LATE-BREAKER SESSION

Moderator: To be confirmed

11.10-11.35
‘An oral SIV vaccine inducing MCH-Ib/E-restricted regulatory CD8+ T-cells suppresses SIV-positive CD4+ T cells and protects macaques against SIV challenge’
Jean-Marie Andrieu, Wei Lu and Song Chen (Universite Montpellier, Montpellier, France)

11.35-11.55
‘A live, attenuated EHEC-based vaccine for C. difficile
Edgar Boedeker, Sudeep Kumar and Wyatt Byrd (The University of New Mexico, Albuquerque, New Mexico, USA)

11.55-12.15
‘The Vaxonella® platform for oral delivery of recombinant vaccines’
Rocky Cranenburgh (Prokarium Ltd, Keele, Staffordshire, UK)

12.15-13.45
Lunch Break & Poster Breakdown

SESSION 11:
VIRAL & CHARACTERIZATION TECHNOLOGY

Moderator: To be confirmed

13.45-14.05
‘Viruses characterization and quantification using tunable resistive pulse sensing’
Dimitri Aubert (Izon Science Ltd, Oxford, UK)

14.05-14.25
‘Nanoparticle Tracking Analysis (NTA): A novel characterization technique for nanoparticles and virus like particles’
Ben Owen, Patrick Hole, Jonathan Smith, Agnieszka Siupa and Bob Carr (NanoSight Ltd, Amesbury, Wiltshire, UK)

14.25-14.55
‘Objective, qualitative and quantitative characterization of viruses and nanoparticles’
Musa Sani (Vironova, Stockholm, Sweden)

14.55-15.10
Tea Break

SESSION 12:
CLOSING PLENARY SESSION

Moderator: Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)

15.10-15.40
Closing Keynote:
‘Mucosal vaccines and adjuvants: What have we learnt and what remains?’

Jan Holmgren (Gothenburg University, Gothenburg, Sweden)

15.40
Closing Remarks & Departure

* This final programme is correct at the time of publishing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final programme.

 

MUCOVAD 2013 Delegates

Login details will be supplied after you have registered for the event.


MUCOVAD 2013 Sponsors

  • Drug Delivery Letters
  • Immune Solutions
  • Current Drug Delivery
  • Nature Gene Therapy
  • Retroscreen Virology
  • Biovaxx
  • PATH
  • Pevion Vaccines
  • Mucosis
  • Univac
  • Izon
  • Inovio Pharmaceuticals
  • Eurocine Vaccines
  • DNA Vaccine
  • Sanofi Pasteur
  • Aldevron

MUCOVAD 2013 Downloads

MUCOVAD 2013 Leaflet

MUCOVAD 2013 Mailing List

Name
E-mail Address
What is 1+4-2?